With all complex clinical trials, MHRA’s top priority is the safety and wellbeing of the trial participants
Similar Posts
Class 4 Medicines Defect Notification: Viatris Products Ltd, Arixtra solution for injection, pre-filled syringes, EL(26)A/04
Viatris has received reports of brown discolouration and blockage in the needle of pre-filled syringes of Arixtra. This quality defect is related to oxidation of the syringe needle.
MHRA phase I accreditation scheme
How to join the phase I accreditation scheme.
Nirogacestat hydrobromide approved to treat desmoid tumours
As with any medicine, the MHRA will keep the safety and effectiveness of Nirogacestat hydrobromide under close review.
MHRA Safety Roundup: November 2025
Summary of the latest safety advice for medicines and medical device users
Keep the warmth, lose the risk: MHRA and National Fire Chiefs Council issue winter emollient safety warning
As colder weather arrives, the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Fire Chiefs Council (NFCC) are urging the public to be aware of fire risks linked to emollient skin creams.
MHRA appoints first Chief Medical and Scientific Officer
Professor Jacob George has been appointed as the first Chief Medical and Scientific Officer for the Medicines and Healthcare products Regulatory Agency (MHRA).